
Johnson & Johnson spin off: what does it mean for JNJ shares?
Johnson & Johnson’s consumer healthcare unit, now called Kenvue, is going public via an IPO. Find out everything we know about the JNJ spin off.
Share this:
Johnson & Johnson’s consumer healthcare unit, now called Kenvue, was valued at $41 billion ahead of its IPO. Shares list on Thursday 4 May. Find out everything we know about the JNJ spin off.
Johnson & Johnson consumer spin off
Kenvue has now been priced at $22 per share, which puts it at the top of the company's marketed range of $20.00 to $23.00. It's estimated the company will raise around $2.8 billion, valuing the new consumer arm of Johnson & Johnson (JNJ) at about $41 billion - and making it the largest IPO in the US since 2021.
Shares start trading on Thursday 4th May on the New York Stock Exchange under the ticker KVUE. After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue’s common stock, representing 91.9% of the total outstanding shares of Kenvue’s common stock.
The consumer arm of JNJ is commonly known for its plasters, baby shampoo and Listerine brand of mouthwash. This move marks the largest restructuring in the company’s 135-year history.
JNJ planned for a tax-free spin off, as they’ll be listing at least 80.1% of the business, which is the minimum required for a tax-free process.
Learn more about how demergers and spin offs work
The consumer division made J&J $15.1 billion in sales in 2021 but is still not as highly valued as other rival consumer units, and not as successful as the other J&J segments. Most of the demand for over-the-counter products were driven by the Tylenol, Neutrogena and Aveeno products, which had market growth during the Covid-19 recovery.
Why is Johnson and Johnson going to split?
Johnson and Johnson’s split is aimed at refocusing the business and streamlining its operations. By removing the consumer arm, Johnson and Johnson will put more into developing medicines and medical devices, which brought in around $80 billion for the firm combined.
The medical arm of JNJ had disappointing sales after competitors’ Covid-19 vaccinations were more successful, but it still has a higher growth outlook. The spin off shouldn’t fundamentally change the operations of either business but will separate the lower-growth consumer unit from the higher-growth segments.
When the market becomes so competitive and high valuations stream in, we see a lot of spin offs occurring to increase shareholder value.
The company’s Chief Financial Officer Joseph Wolk has said previously that the consumer division “…was getting lost within Johnson & Johnson" but the structure also prevented the spotlight from being shone on the pharmaceutical and medical device businesses.
The plans by Johnson and Johnson are part of a much wider trend of large, diversified companies simplifying their structures by demerging various segments and subsidiaries. The strategy seems particularly popular among healthcare businesses, who are moving further into the higher-risk, higher-reward drug field.
Other recent and upcoming spin offs include:
What happens to JNJ stock when the company splits?
Once Johnson and Johnson splits, JNJ stock will only give traders and investors exposure to the medical device and pharmaceutical proceeds of the company. The new company, which will be listed as Kenvue, will trade separately.
The JNJ split is expected to make more shareholder returns, as each business won’t be diluted by the others. Investors will have a clearer image of each division and what makes it attractive.
Following the news, back in November 2021, shares of J&J traded 1.5% higher at $165.55. Over a year later, shares of JNJ are worth over $170 each despite the global economic slowdown. That’s largely because the firm is one of the largest defensive plays on the market, as there is always a demand for consumer health goods and medical products.
After the split, shares of JNJ might not be such a bold defensive play, as the company won’t be as diversified. The sheer scale of operations has somewhat protected JNJ stock from volatility and breaking that up could have a negative impact on the company’s stability.
What does the J&J split mean for shareholders?
If you currently own shares of Johnson & Johnson, when the company splits, you will own shares of both Johnson & Johnson – which will be the new pharmaceutical/medical device business – as well as shares of Kenvue, the new consumer health business.
This will likely come in the form of a special dividend, which is how most spin offs take place.
Related tags:
Latest market news
View more newsOpen an account in minutes
Experience award-winning platforms with fast and secure execution.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

Brazil Elections: Is Investor Confidence Beginning to Fade?
One of the most relevant events for emerging markets in recent sessions has been the outcome of Brazil’s presidential election. Following Lula da Silva’s victory in the second round, investor sentiment began to deteriorate noticeably. This can be observed in both the iShares MSCI Brazil ETF and the VanEck Brazil Small-Cap ETF, two important benchmarks for tracking the Brazilian equity market, both of which have posted declines of more than 15% at the start of the week.

Dow Jones Analysis: Is the DJIA Making a Comeback?
Recent trading sessions have become increasingly relevant for the Dow Jones, as the index has started to regain bullish momentum heading into the end of the week. Over the last three sessions, the DJIA has advanced by more than 0.6%, allowing buying pressure to regain prominence and raising the possibility of a more consistent short-term recovery.

Treasury Auctions Explained: Why Bond Auctions Matter, Even if You Don’t Trade Bonds
You may never trade a Treasury bond, but if you trade the US dollar, gold, or stock indices, US Treasury auctions are worth understanding - read on for everything you need to know!
StoneX Financial Ltd (trading as "FOREX.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, FOREX.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date.
This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it. No opinion given in this material constitutes a recommendation by FOREX.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although FOREX.com is not specifically prevented from dealing before providing this material, FOREX.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. For further details see our full non-independent research disclaimer and quarterly summary.







